Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets

MT Newswires Live

May 08, 2025

Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.

Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.

Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.

Price: 32.16, Change: -0.63, Percent Change: -1.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2533645137"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533645137\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533645137?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533645137","market":"hk","top_or_hot":-1,"title":"Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets","media":"MT Newswires Live","content":"<html><body><p> Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.</p><p>Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.</p><p>Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.</p><p>Price: 32.16, Change: -0.63, Percent Change: -1.91</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwist Bioscience, Ginkgo Bioworks Renegotiate Contract for DNA Technology, Assets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-08 22:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.</p><p>Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.</p><p>Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.</p><p>Price: 32.16, Change: -0.63, Percent Change: -1.91</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4109","symbol_name":"特种化学制品","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2533645137","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533645137","pubTimestamp":1746714828,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Twist Bioscience  and Ginkgo Bioworks  have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.Price: 32.16, Change: -0.63, Percent Change: -1.91","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4109":"特种化学制品","TWST":"Twist Bioscience Corp","DNA":"Ginkgo Bioworks Holdings Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","DNA.AU":"DONACO INTL LTD","BK7078":"赌场与赌博"},"translate_title":"Twist Bioscience与Ginkgo Bioworks重新谈判DNA技术和资产合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNA.AU":1,"TWST":0.9,"DNA":1},"content_text":"Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) have renegotiated a previous contract signed in 2022 to provide Twist with key licenses to long DNA technology and assets, the companies said Thursday.Under the revised $15 million agreement, which runs for three years, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's DNA products. It will also receive preferential pricing for DNA products with no required minimum purchase volume.Twist will receive licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, and Ginkgo will retain the rights to practice the intellectual property transferred to Twist, the announcement states.Price: 32.16, Change: -0.63, Percent Change: -1.91","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}